News headlines about Proteon Therapeutics (NASDAQ:PRTO) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteon Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.1439025729591 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Proteon Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 11th. Robert W. Baird reissued a “hold” rating and set a $2.00 target price on shares of Proteon Therapeutics in a research note on Friday, November 10th. HC Wainwright reaffirmed a “hold” rating and issued a $2.30 price target on shares of Proteon Therapeutics in a research note on Wednesday, November 8th. Oppenheimer Holdings, Inc. reaffirmed a “market perform” rating on shares of Proteon Therapeutics in a research note on Wednesday, August 16th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $6.13.
Proteon Therapeutics (NASDAQ:PRTO) traded up $0.10 during mid-day trading on Monday, reaching $1.90. 34,900 shares of the company’s stock traded hands, compared to its average volume of 112,876. Proteon Therapeutics has a 12 month low of $1.10 and a 12 month high of $11.45.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.